首页> 外文期刊>Journal of clinical laser medicine and surgery >Lumbar percutaneous KTP532 wavelength laser disc decompression and disc ablation in the management of discogenic pain.
【24h】

Lumbar percutaneous KTP532 wavelength laser disc decompression and disc ablation in the management of discogenic pain.

机译:Lumbar percutaneous KTP532 wavelength laser disc decompression and disc ablation in the management of discogenic pain.

获取原文
获取原文并翻译 | 示例
       

摘要

The objective of this research was to determine the outcome of laser disc decompression and laser disc ablation in the management of painful degenerative disc disease with or without associated disc prolapse. Nonendoscopic percutaneous laser disc decompression was performed under x-ray control via the posterolateral approach with side-firing probes. All patients with chronic back pain who had reproduced pain during discography of a nature, pattern, and distribution similar to what they experienced normally were included in the study. Magnetic resonance which confirmed stenosis and sequestrated discs, and patients with acute neurological findings were excluded from the study. Laser disc decompression or ablation was done using the KTP532 wavelength. The functional outcome was assessed prospectively using the Oswestry Disability Index. Clinical benefit was considered significant in those patients with a percentage change in the index of > or =50 at review 3-9 years (mean, 5.33 years) following surgery. A total of 52 of patients demonstrated a sustained significant clinical benefit, with an additional 21 in whom functional improvement was noted. Cohort integrity was 67. Long-term benefit of the laser disc ablation and decompression for discogenic pain suggests a mechanism other than principally mechanical as a cause of chronic back and sciatic pain. It may suggest that efficacy occurs by reduction in the intradiscal production of irritative products and by an effect upon discal and annular neoneuralization. The sustained nature of the benefit after long-term preoperative symptoms (mean, 4.7 years) rules out any placebo effect. Selection should be restricted to patients without significant lateral recess stenosis, retrolisthesis or olisthesis of > or =3 mm, significant dorsal or foraminal osteophytosis, extrusion, or sequestration.

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号